These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 16098255

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM.
    Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S, Tóth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM.
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
    Bhattacharya A, Seshadri M, Oven SD, Tóth K, Vaughan MM, Rustum YM.
    Clin Cancer Res; 2008 Jun 15; 14(12):3926-32. PubMed ID: 18559614
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
    Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM.
    Clin Cancer Res; 2006 Feb 15; 12(4):1237-44. PubMed ID: 16489079
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine.
    Unni E, Kittrell FS, Singh U, Sinha R.
    Breast Cancer Res; 2004 Feb 15; 6(5):R586-92. PubMed ID: 15318939
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles.
    Gao F, Yuan Q, Gao L, Cai P, Zhu H, Liu R, Wang Y, Wei Y, Huang G, Liang J, Gao X.
    Biomaterials; 2014 Oct 15; 35(31):8854-8866. PubMed ID: 25064805
    [Abstract] [Full Text] [Related]

  • 19. Combination of blocking agents and suppressing agents in cancer prevention.
    Ip C, Ganther HE.
    Carcinogenesis; 1991 Feb 15; 12(2):365-7. PubMed ID: 1899813
    [Abstract] [Full Text] [Related]

  • 20. Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression.
    Lee JT, Lee TJ, Park JW, Kwon TK.
    Int J Oncol; 2009 May 15; 34(5):1455-60. PubMed ID: 19360359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.